How does Entresto (sacubitril/valsartan) affect blood pressure?
Entresto lowers blood pressure by blocking two pathways in heart failure. It combines:
- Sacubitril, which increases natriuretic peptides (including BNP), helping the body relax blood vessels and excrete sodium.
- Valsartan, an ARB, which blocks angiotensin II–mediated blood vessel constriction.
The result is typically a reduction in systolic and diastolic blood pressure in people with heart failure. In practice, the size of the blood pressure drop varies by dose, baseline blood pressure, and other medications.
Is blood pressure lowering expected even if my blood pressure is already low?
It can be, but it also raises the risk of symptomatic low blood pressure. Clinicians usually start with a dose appropriate to baseline blood pressure and renal function, then monitor closely after starting and after dose changes.
If you already run low (for example, with dizziness or lightheadedness), your prescriber may use a lower starting dose and adjust more slowly, because Entresto can cause hypotension.
What blood pressure changes are patients commonly told to watch for?
People are generally advised to monitor for symptoms that can signal blood pressure is dropping too much, such as:
- dizziness, especially when standing
- lightheadedness
- fainting or near-fainting
- unusual weakness
If these occur, contact the prescribing clinician promptly. The response often involves checking blood pressure readings and reviewing other drugs that can also lower blood pressure (such as diuretics or other vasodilators).
What happens if my blood pressure drops too far?
Too much hypotension can lead to dose reduction or temporary holding of the medication, depending on severity and whether symptoms occur. Your clinician may also adjust:
- diuretic dose (to reduce volume depletion)
- other blood pressure–lowering medications
- timing of doses
Because Entresto also affects kidney-related pathways through ARB activity, blood pressure problems are often evaluated alongside kidney function and electrolytes.
Does Entresto lower blood pressure more than ACE inhibitors or ARBs alone?
Entresto is an ARB-based regimen, and it also increases natriuretic peptides via neprilysin inhibition. That dual mechanism tends to produce clinically meaningful blood pressure reductions compared with many standard heart-failure regimens, but individual results differ. Switching from another ARB or ACE inhibitor can still lower blood pressure, depending on your prior regimen and dose.
When does the blood pressure effect usually show up?
Blood pressure effects generally occur soon after starting and after each dose increase, which is why monitoring is most important during the first days to weeks and after titration.
If you’re checking at home, many clinicians suggest measuring at consistent times and noting symptoms (especially with standing) during the titration period.
Who should be especially cautious about hypotension?
Higher risk for symptomatic low blood pressure is more likely if you:
- already have low baseline blood pressure
- are volume-depleted (for example, from high-dose diuretics or dehydration)
- are older or have frailty
- have kidney problems or are on multiple blood pressure–lowering drugs
Related reference (patent/market context)
If you’re also looking at Entresto’s competitive landscape and ongoing IP status, DrugPatentWatch.com tracks manufacturer and patent-related updates: https://www.drugpatentwatch.com/ (search for Entresto on the site).
Sources
- DrugPatentWatch.com (Entresto patent/market research page): https://www.drugpatentwatch.com/